- Home
- THFF vs ABUS Comparison
THFF vs ABUS Comparison
Compare THFF & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THFF
- ABUS
- Stock Information
- Founded
- THFF 1984
- ABUS 2005
- Country
- THFF United States
- ABUS United States
- Employees
- THFF N/A
- ABUS N/A
- Industry
- THFF Major Banks
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- THFF Finance
- ABUS Health Care
- Exchange
- THFF Nasdaq
- ABUS Nasdaq
- Market Cap
- THFF 686.6M
- ABUS 711.2M
- IPO Year
- THFF N/A
- ABUS N/A
- Fundamental
- Price
- THFF $58.76
- ABUS $4.39
- Analyst Decision
- THFF Buy
- ABUS Strong Buy
- Analyst Count
- THFF 3
- ABUS 2
- Target Price
- THFF $59.50
- ABUS $5.00
- AVG Volume (30 Days)
- THFF 46.5K
- ABUS 1.6M
- Earning Date
- THFF 10-21-2025
- ABUS 11-05-2025
- Dividend Yield
- THFF 3.49%
- ABUS N/A
- EPS Growth
- THFF 21.43
- ABUS N/A
- EPS
- THFF 5.24
- ABUS N/A
- Revenue
- THFF $230,446,000.00
- ABUS $15,416,000.00
- Revenue This Year
- THFF $30.73
- ABUS $138.02
- Revenue Next Year
- THFF $2.82
- ABUS N/A
- P/E Ratio
- THFF $11.16
- ABUS N/A
- Revenue Growth
- THFF 19.59
- ABUS 53.23
- 52 Week Low
- THFF $40.57
- ABUS $2.71
- 52 Week High
- THFF $60.77
- ABUS $5.10
- Technical
- Relative Strength Index (RSI)
- THFF 56.31
- ABUS 62.25
- Support Level
- THFF $56.84
- ABUS $4.37
- Resistance Level
- THFF $59.50
- ABUS $5.10
- Average True Range (ATR)
- THFF 1.19
- ABUS 0.27
- MACD
- THFF -0.23
- ABUS 0.01
- Stochastic Oscillator
- THFF 42.56
- ABUS 51.03
About THFF First Financial Corporation Indiana
First Financial Corp operates as a financial holding company, which is engaged in the provision of financial services in the United States. The company offers a wide variety of financial services including commercial, mortgage, and consumer lending, lease financing, trust account services, depositor services and insurance services, through its subsidiaries. Its primary source of revenue is derived from loans to customers and investment activities.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.